Coherus Biosciences | CHRS - Assets


Coherus Biosciences reported $258.34M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
AbbVie USD 133.96B 62M Dec/2025
Acadia Pharmaceuticals USD 1.56B 233.42M Dec/2025
Akebia Therapeutics USD 376.56M 12.41M Dec/2025
ALKERMES USD 2.49B 157.48M Dec/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
Amarin USD 670.78M 10.96M Dec/2025
Amgen USD 90.59B 445M Dec/2025
Baxter International USD 20.06B 1.01B Dec/2025
Biogen USD 29.44B 232M Dec/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Coherus Biosciences USD 258.34M 258.18M Dec/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Fujifilm JPY 5.88T 349.29B Dec/2025
Gilead Sciences USD 59.02B 490M Dec/2025
Ironwood Pharmaceuticals USD 396.06M 53.12M Sep/2025
Merck USD 129.55B 12.02B Sep/2025
Myriad Genetics USD 706.6M 21.5M Dec/2025
Pacira USD 1.26B 32.66M Dec/2025
Perrigo USD 8.54B 1.55B Dec/2025
Pfizer USD 208.73B 2.64B Sep/2025
PTC Therapeutics USD 2.9B 255.07M Dec/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Sarepta Therapeutics USD 3.35B 143.73M Dec/2025
Teva Pharmaceutical Industries USD 40.75B 892M Dec/2025
Vertex Pharmaceuticals USD 25.64B 780.7M Dec/2025
Xencor USD 875.5M 6.68M Dec/2025
Zoetis USD 15.47B 308M Dec/2025